Core Insights - The pharmaceutical industry is witnessing significant strategic collaborations, with companies like Kangzheng Pharmaceutical partnering with global giants like Novartis to enhance their market presence in specialized fields such as ophthalmology and dermatology [1] Group 1: Kangzheng Pharmaceutical's Strategic Moves - Kangzheng Pharmaceutical has signed a distribution agreement with Novartis, gaining exclusive rights for two ophthalmic drugs in mainland China, indicating a strong commitment to the ophthalmology sector [1] - The company is also focusing on its dermatology segment through the spin-off of its skin health business, Dermy Pharmaceuticals, which has submitted a listing application to the Hong Kong Stock Exchange [1] Group 2: Market Potential in Dermatology - The white spot disease (vitiligo) market is highlighted as a significant opportunity, with the treatment market projected to grow from 2.8 billion RMB in 2024 to approximately 21.9 billion RMB by 2035, reflecting a compound annual growth rate (CAGR) of 20.7% [2] - Dermy Pharmaceuticals is advancing its lead product, Ruxolitinib cream, which is the first and only FDA and EMA-approved topical JAK inhibitor for vitiligo, currently in the new drug application approval stage in China [3] Group 3: Other Dermatological Conditions - Psoriasis, affecting around 7.2 million patients in China, is seeing a shift towards biologics and small molecule drugs as preferred treatment options, with Dermy Pharmaceuticals' Tildrakizumab injection positioned as a second approved IL-23 monoclonal antibody in the market [4] - Atopic dermatitis, impacting over 54 million people in China, is expected to see its treatment market grow from 12.1 billion RMB in 2024 to 39.4 billion RMB by 2035, with Dermy Pharmaceuticals pursuing multiple pipeline strategies to address this demand [6][7] Group 4: Acne Treatment Innovations - Acne is a prevalent skin issue, with a reported prevalence of 8.1% in the Chinese population, leading to a growing market for effective skincare solutions [8] - Dermy Pharmaceuticals is leveraging its brand advantage with the launch of the Xiliao Duo series, targeting acne treatment and prevention, while also offering soothing products for atopic dermatitis and sensitive skin [8]

Core Viewpoint - 德镁医药有限公司 has submitted an application for listing on the Hong Kong Stock Exchange, with its skin prescription drug revenue ranking first among innovative pharmaceutical companies in China and fifth overall among all Chinese pharmaceutical companies [1] Group 1: Company Overview - 德镁医药 is a leading Chinese pharmaceutical company focused on innovative skin health products, providing integrated solutions for skin health from prevention to treatment and long-term care [1] - The company was spun off from 康哲药业 (CMS) in 2021 and the listing will not involve new share issuance or fundraising [1] Group 2: Product Portfolio - 德镁医药 has established a diverse product portfolio addressing significant unmet clinical needs in major skin diseases, ranking first among innovative pharmaceutical companies in China for the coverage of seven skin disease indications [2] - The main products include skin prescription drugs and dermatological-grade skincare products, with a pipeline that includes three marketed products and several candidates in clinical stages [2] Group 3: Commercialization Capability - The company has a proven track record of commercialization, supported by a strong sales and academic promotion team of approximately 650 professionals [3] - 德镁医药 has a wide sales network covering over 12,000 hospitals and 150,000 retail pharmacies across China, with significant revenue coming from outpatient channels [3] Group 4: Financial Performance - For the fiscal years 2022 to 2025, the company reported revenues of 384 million, 473 million, 618 million, and 498 million RMB respectively, with net losses recorded during the same periods due to high sales and R&D expenses [4] - The losses were primarily attributed to the costs associated with promoting newly acquired or launched products and expanding the product pipeline [4]

Core Viewpoint - 德镁医药有限公司 has submitted its listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, indicating a strong position in the innovative skin prescription drug market in China [1][3]. Company Overview - 德镁医药 was spun off from 康哲药业 (CMS) in 2021 and is focused on innovative skin health products, providing integrated solutions from prevention to long-term care [3]. - The company ranks first among Chinese pharmaceutical companies focusing on innovative products in terms of revenue generated from skin prescription drugs for 2024, and fifth overall among all Chinese pharmaceutical companies [1][3]. Product Portfolio - 德镁医药 has a diverse product portfolio that addresses significant unmet clinical needs in major skin diseases, with a leading position in the coverage of seven skin disease indications among innovative product-focused Chinese pharmaceutical companies [3]. - The main products include skin prescription drugs and dermatological-grade skincare products, with a pipeline that includes three marketed products and several candidates in various stages of clinical development [4]. Commercialization and Sales Network - The company has a strong commercialization capability, supported by a dedicated team of approximately 650 professionals, and has established a comprehensive sales network covering over 12,000 hospitals and 150,000 retail pharmacies across China [5]. - 德镁医药's sales revenue is significantly derived from outpatient channels, and it holds a leading position in the coverage of hospital dermatology departments in China [5]. Financial Performance - For the fiscal years ending December 31 and the six months ending June 30, the company reported revenues of RMB 384 million, RMB 473 million, RMB 618 million, and RMB 498 million for 2022, 2023, 2024, and the first half of 2025, respectively [6][7]. - The company recorded net losses during the performance period, primarily due to high sales and R&D expenses associated with new product launches and pipeline expansion [6].

Core Viewpoint - Demy Pharmaceutical Co., Ltd. is seeking to list on the Hong Kong Stock Exchange, focusing on prescription dermatological drugs and skincare products, with a significant growth trajectory in revenue and product pipeline [2][11]. Company Overview - Demy Pharmaceutical was established in 2020 and is headquartered in Haikou, Hainan Province. It was spun off from CMS Group in 2021 and operates independently [2][3]. - The company employs a dual approach of collaborative and independent research and development, targeting innovative products in the dermatology sector [3]. Product Pipeline - As of April 15, 2025, Demy has three marketed products and several candidates in various clinical stages, addressing major skin diseases such as psoriasis, vitiligo, and atopic dermatitis [3][10]. - Key products include: - **Rituximab Injection (Yilvqu)**: Approved for moderate to severe plaque psoriasis, requiring administration only four times a year [7]. - **Polysaccharide Mucopolysaccharide Cream (Xiliao)**: A skin barrier repair agent approved for treating bruises and superficial venous inflammation [8]. - **Lukotini Cream**: A JAK inhibitor for vitiligo, currently under NDA review in China [8]. - **MG-K10**: A long-acting monoclonal antibody for atopic dermatitis, completing Phase III trials in China [9]. Financial Performance - Revenue growth has been driven by increased sales of dermatological prescription drugs and skincare products, with revenues of 384 million RMB, 473 million RMB, and 618 million RMB for 2022, 2023, and 2024 respectively [11][12]. - The company reported net losses of 55.2 million RMB, 4.7 million RMB, and 106 million RMB during the same periods, primarily due to high sales and R&D expenses [12]. - Total R&D expenditures were 291 million RMB, 187 million RMB, and 265 million RMB, representing 76.0%, 39.5%, and 42.9% of total revenue for the respective periods [15]. Market Potential - The dermatology treatment and care market in China is projected to grow from 76.4 billion RMB in 2023 to a compound annual growth rate (CAGR) of 10.6% through 2035 [10]. - The market for atopic dermatitis treatments is expected to reach 12.3 billion RMB in 2024, growing to 24.7 billion RMB by 2029 [10]. Operational Scale - As of March 31, 2025, Demy employed 764 full-time staff, with a commercialization team of 650, and its sales network covers over 10,000 hospitals and 100,000 retail pharmacies across China [12].

Core Viewpoint - 康哲药业's subsidiary 德镁医药 is planning to spin off and independently list on the Hong Kong Stock Exchange, despite facing losses in recent years [1][2] Group 1: Company Overview - 德镁医药 is primarily responsible for 康哲药业's skin health business in China, focusing on innovative pharmaceutical solutions for skin conditions [1] - The company has developed a diverse product portfolio addressing significant unmet clinical needs in major skin disease areas, including three marketed prescription products for conditions like psoriasis [1] Group 2: Financial Performance - 德镁医药 has reported losses for the past three years, with revenues of 383 million yuan, 473 million yuan, and 618 million yuan from 2022 to 2024, while net profits were -55.17 million yuan, -4.703 million yuan, and -106 million yuan respectively [2] - The revenue growth is attributed to increased sales of prescription drugs and dermatological skincare products, while losses are mainly due to high marketing and R&D expenses related to new product launches [2] Group 3: Spin-off Purpose - The spin-off aims to allow 德镁医药 to raise capital directly from the market, providing financial support for its existing operations and future expansion [2] - After the spin-off, 康哲药业 will no longer hold any equity in 德镁医药, which will cease to be a subsidiary [2]

Group 1 - The core point of the article is that Kangzheng Pharmaceutical is planning to spin off its subsidiary, Demai Pharmaceutical, which holds 90.8% of its shares, to list on the Hong Kong Stock Exchange, aiming to enhance both companies' market positions and attract investors [1][4] - Demai Pharmaceutical, established in 2020, focuses on skin prescription drugs and dermatological skincare products, providing comprehensive solutions for skin health [2][5] - The company has a product pipeline that includes three marketed products and several candidates in various stages of development, targeting common skin diseases such as psoriasis and acne [2][3] Group 2 - Demai Pharmaceutical reported revenues of approximately 1.5 billion yuan over the past three years, with a net loss of 160 million yuan, indicating a trend of increasing revenue but persistent losses [2][3] - The revenue growth is attributed to increased sales of skin prescription drugs and dermatological skincare products, alongside high promotional and R&D expenses [5][6] - The spin-off is expected to provide Demai Pharmaceutical with greater autonomy in resource allocation and strategic decision-making, potentially leading to improved operational efficiency and market opportunities in the skin health sector [6][7]

星标 ★ IPO日报 精彩文章第一时间推送 近日，康哲药业(00867.HK)发布公告，建议将旗下皮肤业务附属公司德镁医药股份分拆并在港交所主板独立上市。 同时，德镁医药有限公司（下称"德镁医药"）向港交所提交了上市申请，独家保荐人为华泰国际。 需要指出的是，康哲药业此次分拆将以实物方式向其股东分派其持有的所有德镁医药股份，而德镁医药以介绍方式在香港主板上市。 制图：佘诗婕 分拆 资料显示，康哲药业是一家开曼群岛注册的有限公司，在2010年9月登陆港交所主板，聚焦于心脑血管、中枢神经、消化及眼科等专科 业务，以及港、澳、台及东南亚市场的皮肤健康业务。创新药方面，公司已累计有5款创新药进入商业化，包括莱芙兰、美泰彤、维福 瑞、益路取和维图可，重磅单品芦可替尼有望2025年内实现销售。 康哲药业目前市值约208亿港元（约合人民币195.31亿元），自从4月22日发布分拆消息后，股价连续上涨三个交易日。 据最新披露，康哲药业2024年实现营业收入74.7亿元，同比下降6.8%；年度溢利16.1亿元，同比下滑32.3%，经调整后净利润为17.1亿 元，同比下降36.7%。 按照全药品销售收入口径来看，2024年，公司 ...